Selvita Expands its Proteomics Services Offer
Selvita has expanded its portfolio of protein chemistry services.
Analysis, production and purification of recombinant proteins remain the major activities of Selvita’s Protein Chemistry Laboratory. These projects require high expertise in the design of genetic constructs, determination and selection of the optimal expression conditions and finally production and purification of recombinant proteins with highest purity and biological activity.
“Being aware of the importance of the protein targets at every step of the preclinical drug discovery process, we place a great emphasis on the quality of our protein products. The highest purity and biological activity of the proteins, which we deliver to our customers, are our major objective and concern,” said Dr Justyna Stec-Niemczyk, Head of the Protein Chemistry Laboratory.
Due to the dynamic development of the Protein Chemistry Laboratory and constantly increasing portfolio of customers, Selvita is currently increasing its capabilities in terms of proteomic analyses. These analyses can be used for instance for biosimilar product characterization, which are currently of high interest to many biotechnology companies. Expansion of the service offer is possible due to the access to the extended range of the state of the art scientific equipment. This includes highly sophisticated mass spectrometers (e.g., MALDI-TOF MS microflex LT, LC/MS ESI/Apci Q-TOF plus, LC/MS/TSQ, LC/RAPID/MS/DAD/ESI/IT), additional ultra HPLC systems with the range of the specialized detectors (e.g. UV-VIS, RI, DAD, ELSD, Corona CAD, MALS, DLS, FLD); and microscale thermophoresis measurement devices (Nanotemper Monolith NT).
Selvita’s protein chemistry offer, in addition to already available services such as, protein assays and PAGE patterns, LC services, N-terminal protein sequencing and amino acid analyses, CD spectra analyses and the crystallographic studies, now also includes
• Determination of intact mass of proteins including large proteins,
• Analysis of the posttranslational modifications,
• Determination of protein oligomeric state (quaternary structure) and aggregation
• Protein conformation stability
• Biophysical methods for the determination of various parameters of protein-protein and protein-ligand interactions.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance